MEK Pathway Inhibitor-Mediated Response in BRAF V600-Mutant Melanoma with Brain Parenchymal and Leptomeningeal Metastases

Saud Alhusaini MD, PhD

Department of Neurology, Warren Alpert Medical School, Brown University, Providence, RI, USA

Search for more papers by this author

Lewis Naya BA

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA

Search for more papers by this author

Sunil A. Reddy MD

Division of Melanoma Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

Search for more papers by this author

Corresponding Author

Chirag B. Patel MD, PhD

• [email protected]

• orcid.org/0000-0003-0787-0634
• @CPatel_Lab

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Cancer Biology Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA

Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA

Address correspondence to Dr Chirag B. Patel, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1002, BSRB S5.8116b, Houston, TX 77030, USA. E-mail: [email protected]

Search for more papers by this author